Lysyl oxidase contributes to mechanotransduction-mediated regulation of transforming growth factor-β signaling in breast cancer cells

Neoplasia

Volumn 13, Issue 5, 2011, Pages 406-418

  Taylor, Molly A ^a   Amin, Jay D ^b   Kirschmann, Dawn A ^c   Schiemann, William P ^d  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; CYTOKERATIN 19; FIBRONECTIN; HYDROGEN PEROXIDE; MITOGEN ACTIVATED PROTEIN KINASE P38; NERVE CELL ADHESION MOLECULE; PROTEIN LYSINE 6 OXIDASE; PROTEIN LYSINE 6 OXIDASE L1; PROTEIN LYSINE 6 OXIDASE L2; PROTEIN LYSINE 6 OXIDASE L3; SHORT HAIRPIN RNA; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; AUTOCRINE EFFECT; BREAST CANCER; BREAST CARCINOGENESIS; BREAST EPITHELIUM; CANCER CELL; CANCER CELL CULTURE; CANCER GROWTH; CATALYSIS; CELL CULTURE; CELL INVASION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME RELEASE; ENZYME SYNTHESIS; EPITHELIAL MESENCHYMAL TRANSITION; EXTRACELLULAR MATRIX; MECHANOTRANSDUCTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION;

EID: 79955852383     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.101086     Document Type: Article

References (57)

1. Chang CF, Westbrook R, Ma J, and Cao D (2007). Transforming growth factor-βsignaling in breast cancer. Front Biosci 12, 4393-4401.
2. Tian M and Schiemann WP (2009). The TGF-β paradox in human cancer: anupdate. Future Oncol 5, 259-271.
3. Galliher AJ, Neil JR, and Schiemann WP (2006). Role of transforming growthfactor-β in cancer progression. Future Oncol 2, 743-763.
4. Wendt MK and Schiemann WP (2009). Therapeutic targeting of the focal adhesioncomplex prevents oncogenic TGF-β signaling and metastasis. Breast CancerRes 11, R68.
5. Moustakas A and Heldin CH (2005). Non-Smad TGF-β signals. J Cell Sci 118, 3573-3584.
6. Galliher AJ and Schiemann WP (2006). β3 integrin and Src facilitate transforminggrowth factor-β mediated induction of epithelial-mesenchymal transition inmammary epithelial cells. Breast Cancer Res 8, R42.
7. Galliher AJ and Schiemann WP (2007). Src phosphorylates Tyr284 in TGF-βtype II receptor and regulates TGF-β stimulation of p38 MAPK during breastcancer cell proliferation and invasion. Cancer Res 67, 3752-3758.
8. Galliher-Beckley AJ and Schiemann WP (2008). Grb2 binding to Tyr284 inTβR-II is essential for mammary tumor growth and metastasis stimulated byTGF-β. Carcinogenesis 29, 244-251.
9. Wendt MK, Smith JA, and Schiemann WP (2009). p130Cas is required formammary tumor growth and TGF-β-mediated metastasis through regulationof Smad2/3 activity. J Biol Chem 284, 31145-31156.
10. Payne SL, Hendrix MJ, and Kirschmann DA (2007). Paradoxical roles for lysyloxidases in cancer-a prospect. J Cell Biochem 101, 1338-1354.
11. Kagan HM and Li W (2003). Lysyl oxidase: properties, specificity, and biologicalroles inside and outside of the cell. J Cell Biochem 88, 660-672.
12. Butcher DT, Alliston T, and Weaver VM (2009). A tense situation: forcing tumourprogression. Nat Rev Cancer 9, 108-122.
13. Erler JT, Bennewith KL, Cox TR, Lang G, Bird D, Koong A, Le QT, and Giaccia AJ (2009). Hypoxia-induced lysyl oxidase is a critical mediator of bone marrowcell recruitment to form the premetastatic niche. Cancer Cell 15, 35-44.
14. Paszek MJ, Zahir N, Johnson KR, Lakins JN, Rozenberg GI, Gefen A, Reinhart-King CA, Margulies SS, Dembo M, Boettiger D, et al. (2005). Tensional homeostasisand the malignant phenotype. Cancer Cell 8, 241-254.
15. Levental KR, Yu H, Kass L, Lakins JN, Egeblad M, Erler JT, Fong SF, Csiszar K, Giaccia A, Weninger W, et al. (2009). Matrix crosslinking forces tumor progressionby enhancing integrin signaling. Cell 139, 891-906.
16. Erler JT, Bennewith KL, Nicolau M, Dornhofer N, Kong C, Le QT, Chi JT, Jeffrey SS, and Giaccia AJ (2006). Lysyl oxidase is essential for hypoxia-inducedmetastasis. Nature 440, 1222-1226.
17. Kirschmann DA, Seftor EA, Fong SF, Nieva DR, Sullivan CM, Edwards EM, Sommer P, Csiszar K, and Hendrix MJ (2002). A molecular role for lysyl oxidasein breast cancer invasion. Cancer Res 62, 4478-4483.
18. Barry-Hamilton V, Spangler R, Marshall D, McCauley S, Rodriguez HM, Oyasu M, Mikels A, Vaysberg M, Ghermazien H, Wai C, et al. (2010). Allostericinhibition of lysyl oxidase-like-2 impedes the development of a pathologicmicroenvironment. Nat Med 16, 1009-1017.
19. Payne SL, Hendrix MJ, and Kirschmann DA (2006). Lysyl oxidase regulatesactin filament formation through the p130(Cas)/Crk/DOCK180 signalingcomplex. J Cell Biochem 98, 827-837.
20. Allington TM, Galliher-Beckley AJ, and Schiemann WP (2009). Activated Ablkinase inhibits oncogenic transforming growth factor-β signaling and tumorigenesisin mammary tumors. FASEB J 23, 4231-4243.
21. Tang B, Vu M, Booker T, Santner SJ, Miller FR, Anver MR, and Wakefield LM(2003). TGF-β switches from tumor suppressor to prometastatic factor in amodel of breast cancer progression. J Clin Invest 112, 1116-1124.
22. Sokol JP and Schiemann WP (2004). Cystatin C antagonizes transforming growthfactorβ signaling in normal and cancer cells. Mol Cancer Res 2, 183-195.
23. Payne SL, Fogelgren B, Hess AR, Seftor EA, Wiley EL, Fong SF, Csiszar K, Hendrix MJ, and Kirschmann DA (2005). Lysyl oxidase regulates breast cancercell migration and adhesion through a hydrogen peroxide-mediated mechanism.Cancer Res 65, 11429-11436.
24. Schiemann WP, Pfeifer WM, Levi E, Kadin ME, and Lodish HF (1999). Adeletion in the gene for transforming growth factorβ type I receptor abolishesgrowth regulation by transforming growth factorβ in a cutaneous T-cell lymphoma.Blood 94, 2854-2861.
25. Schiemann WP, Blobe GC, Kalume DE, Pandey A, and Lodish HF (2002).Context-specific effects of fibulin-5 (DANCE/EVEC) on cell proliferation, motility, and invasion. Fibulin-5 is induced by transforming growth factor-β andaffects protein kinase cascades. J Biol Chem 277, 27367-27377.
26. Albig AR and Schiemann WP (2005). Identification and characterization of regulatorof G protein signaling 4 (RGS4) as a novel inhibitor of tubulogenesis:RGS4 inhibits mitogen-activated protein kinases and vascular endothelial growthfactor signaling. Molecular Biol Cell 16, 609-625.
27. Sokol JP, Neil JR, Schiemann BJ, and Schiemann WP (2005). The use of cystatin Cto inhibit epithelial-mesenchymal transition and morphological transformationstimulated by transforming growth factor-β. Breast Cancer Res 7, R844-R853.
28. Neil JR, Johnson KM, Nemenoff RA, and Schiemann WP (2008). COX-2 inactivatesSmad signaling and enhances EMT stimulated by TGF-β through aPGE2-dependent mechanism. Carcinogenesis 29, 2227-2235.
29. Lee GY, Kenny PA, Lee EH, and Bissell MJ (2007). Three-dimensional culturemodels of normal and malignant breast epithelial cells. Nat Methods 4, 359-365.
30. Schiemann BJ, Neil JR, and Schiemann WP (2003). SPARC inhibits epithelialcell proliferation in part through stimulation of the transforming growth factor-β-signaling system. Mol Biol Cell 14, 3977-3988.
31. Wendt MK, Allington TM, and Schiemann WP (2009). Mechanisms of theepithelial-mesenchymal transition by TGF-β. Future Oncol 5, 1145-1168.
32. Bakin AV, Rinehart C, Tomlinson AK, and Arteaga CL (2002). p38 mitogen-activated protein kinase is required for TGFβ-mediated fibroblastic transdifferentiationand cell migration. J Cell Sci 115, 3193-3206.
33. Bhowmick NA, Zent R, Ghiassi M, McDonnell M, and Moses HL (2001).Integrinβ1 signaling is necessary for transforming growth factor-β activationof p38MAPK and epithelial plasticity. J Biol Chem 276, 46707-46713.
34. Valcourt U, Kowanetz M, Niimi H, Heldin CH, and Moustakas A (2005).TGF-β and the Smad signaling pathway support transcriptomic reprogrammingduring epithelial-mesenchymal cell transition. Mol Biol Cell 16, 1987-2002.
35. Kim Y, Kugler MC, Wei Y, Kim KK, Li X, Brumwell AN, and Chapman HA(2009). Integrin α3β1-dependentβ-catenin phosphorylation links epithelialSmad signaling to cell contacts. J Cell Biol 184, 309-322.
36. Saika S, Kono-Saika S, Ohnishi Y, Sato M, Muragaki Y, Ooshima A, Flanders KC, Yoo J, Anzano M, Liu CY, et al. (2004). Smad3 signaling is required forepithelial-mesenchymal transition of lens epithelium after injury. Am J Pathol164, 651-663.
37. Postovit LM, Abbott DE, Payne SL, Wheaton WW, Margaryan NV, Sullivan R, Jansen MK, Csiszar K, Hendrix MJ, and Kirschmann DA (2008). Hypoxia/reoxygenation: a dynamic regulator of lysyl oxidase-facilitated breast cancer migration.J Cell Biochem 103, 1369-1378.
38. Wrighton KH, Lin X, and Feng XH (2009). Phospho-control of TGF-β superfamilysignaling. Cell Res 19, 8-20.
39. Erler JT and Weaver VM (2009). Three-dimensional context regulation of metastasis.Clin Exp Metastasis 26, 35-49.
40. Neil JR and Schiemann WP (2008). Altered TAB1:IκB kinase interaction promotestransforming growth factorβ-mediated nuclear factor-κB activation duringbreast cancer progression. Cancer Res 68, 1462-1470.
41. Tian M and Schiemann WP (2009). PGE2 receptor EP2 mediates the antagonisticeffect of COX-2 on TGF-β signaling during mammary tumorigenesis. FASEB J 24, 1105-1116.
42. Tian M and Schiemann WP (2009). Preclinical efficacy of cystatin C to targetthe oncogenic activity of transforming growth factorβ in breast cancer. TranslOncol 2, 174-183.
43. Neil JR, Tian M, and Schiemann WP (2009). x-linked inhibitor of apoptosisprotein and its E3 ligase activity promote transforming growth factor-β-mediatednuclear factor-κB activation during breast cancer progression. J Biol Chem 284, 21209-21217.
44. Wells A, Yates C, and Shepard CR (2008). E-cadherin as an indicator of mesenchymalto epithelial reverting transitions during the metastatic seeding of disseminatedcarcinomas. Clin Exp Metastasis 25, 621-628.
45. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, and Thun MJ (2008).Cancer statistics, 2008. CA Cancer J Clin 58, 71-96.
46. Kass L, Erler JT, Dembo M, and Weaver VM (2007). Mammary epithelial cell:influence of extracellular matrix composition and organization during developmentand tumorigenesis. Int J Biochem Cell Biol 39, 1987-1994.
47. Paszek MJ and Weaver VM (2004). The tension mounts: mechanics meets morphogenesisand malignancy. J Mammary Gland Biol Neoplasia 9, 325-342.
48. Weaver VM, Petersen OW, Wang F, Larabell CA, Briand P, Damsky C, andBissell MJ (1997). Reversion of the malignant phenotype of human breast cellsin three-dimensional culture and in vivo by integrin blocking antibodies. J CellBiol 137, 231-245.
49. Wang F, Weaver VM, Petersen OW, Larabell CA, Dedhar S, Briand P, Lupu R, and Bissell MJ (1998). Reciprocal interactions betweenβ1-integrin and epidermalgrowth factor receptor in three-dimensional basement membrane breast cultures:a different perspective in epithelial biology. Proc Natl Acad Sci USA 95, 14821-14826.
50. Kim YM, Kim EC, and Kim Y (2011). The human lysyl oxidase-like 2 proteinfunctions as an amine oxidase toward collagen and elastin. Mol Biol Rep 38, 145-149.
51. Schietke R, Warnecke C, Wacker I, Schodel J, Mole DR, Campean V, Amann K, Goppelt-Struebe M, Behrens J, Eckardt KU, et al. (2010). The lysyl oxidasesLOX and LOXL2 are necessary and sufficient to repress E-cadherin in hypoxia:insights into cellular transformation processes mediated by HIF-1. J Biol Chem285, 6658-6669.
52. Yang L, Huang J, Ren X, Gorska AE, Chytil A, Aakre M, Carbone DP, Matrisian LM, Richmond A, Lin PC, et al. (2008). Abrogation of TGFβ signalingin mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promotemetastasis. Cancer Cell 13, 23-35.
53. Goodman VL, Brewer GJ, and Merajver SD (2004). Copper deficiency as ananti-cancer strategy. Endocr Relat Cancer 11, 255-263.
54. Erler JT and Giaccia AJ (2006). Lysyl oxidase mediates hypoxic control of metastasis.Cancer Res 66, 10238-10241.
55. Lopez JI, Mouw JK, and Weaver VM (2008). Biomechanical regulation of cellorientation and fate. Oncogene 27, 6981-6993.
56. Kumar S and Weaver VM (2009). Mechanics, malignancy, and metastasis: theforce journey of a tumor cell. Cancer Metastasis Rev 28, 113-127.
57. Wendt MK, Smith JA, and Schiemann WP (2010). Transforming growth factor-β-induced epithelial-mesenchymal transition facilitates epidermal growth factor-dependent breast cancer progression. Oncogene 29, 6485-6498.